B. Riley Securities analyst Bryce Rowe reinstates Monroe Cap (NASDAQ:MRCC) with a Neutral and announces $8 price target.
200% Gain In One Day – Why Is Heart Failure Focused BioCardia Stock Soaring Today?
The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for